|
Building upon our strong base of operations in Western Europe, Kendle now offers expanded coverage in Northern Europe through our office in Uppsala, Sweden. This office further strengthens our global clinical development capabilities in the Phase II–IV arena, and covers not only Sweden, but Denmark, Finland and Norway as well.
Sweden has fast become a popular European base for clinical research. Since the Clinical Trials Directive was implemented in May 2004, 10 percent of all clinical trials in the European Union have been registered in Sweden. Given Sweden’s relatively small population (9,031,088, approximately 1.5 percent of EU),(1) this is a large proportion of Europe’s clinical trials.
What makes Sweden so popular for clinical research? First, the country’s efficient approval process, high-quality data and widely-respected regulatory agency make it a consistently ideal location for the conduct of clinical trials. In addition, its unique public health system allows for high enrollment rates, low drop out rates and the successful long-term tracking of patients.(2) The Swedish government is in full support of expanding clinical research and testing, attracting more doctors into research and strengthening the country’s pharmaceutical industry. Consequently, it has invested $24 million to encourage the industry.(3)
As well as a strong international position in brain science,(2) Sweden also has a leading position in neuronal stem cell research,(4) making it an excellent location for central nervous system research. In addition, Sweden has a strong biotech industry.(2)
- central nervous system
- cardiovascular
- gastrointestinal
- dermatology
- rheumatoid arthritis
|
